141 related articles for article (PubMed ID: 2470738)
1. Functional characterization of monoclonal antibodies directed against fibrin binding domains of tissue-type plasminogen activator.
Wojta J; Beckmann R; Turcu L; Wagner OF; van Zonneveld AJ; Binder BR
J Biol Chem; 1989 May; 264(14):7957-61. PubMed ID: 2470738
[TBL] [Abstract][Full Text] [Related]
2. Interaction of plasminogen and fibrin in plasminogen activation.
Wu HL; Chang BI; Wu DH; Chang LC; Gong CC; Lou KL; Shi GY
J Biol Chem; 1990 Nov; 265(32):19658-64. PubMed ID: 2174048
[TBL] [Abstract][Full Text] [Related]
3. The dissociation constants and stoichiometries of the interactions of Lys-plasminogen and chloromethyl ketone derivatives of tissue plasminogen activator and the variant delta FEIX with intact fibrin.
Nesheim M; Fredenburgh JC; Larsen GR
J Biol Chem; 1990 Dec; 265(35):21541-8. PubMed ID: 2123871
[TBL] [Abstract][Full Text] [Related]
4. Introduction of lysine and clot binding properties in the kringle one domain of tissue-type plasminogen activator.
Bakker AH; van der Greef W; Rehberg EF; Marotti KR; Verheijen JH
J Biol Chem; 1993 Sep; 268(25):18496-501. PubMed ID: 8395505
[TBL] [Abstract][Full Text] [Related]
5. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
Berg DT; Burck PJ; Berg DH; Grinnell BW
Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
[TBL] [Abstract][Full Text] [Related]
6. A monoclonal antibody preventing binding of tissue-type plasminogen activator to fibrin: useful to monitor fibrinogen breakdown during t-PA infusion.
Holvoet P; Lijnen HR; Collen D
Blood; 1986 May; 67(5):1482-7. PubMed ID: 3083892
[TBL] [Abstract][Full Text] [Related]
7. Stimulation of the amidolytic activity of single chain tissue-type plasminogen activator by fibrinogen degradation products: possible fibrin binding sites on single chain tissue-type plasminogen activator molecule.
Urano T; Takada Y; Takada A
Biochim Biophys Acta; 1991 Apr; 1077(3):245-52. PubMed ID: 1903067
[TBL] [Abstract][Full Text] [Related]
8. Interactions between the finger and kringle-2 domains of tissue-type plasminogen activator and plasminogen activator inhibitor-1.
Kaneko M; Sakata Y; Matsuda M; Mimuro J
J Biochem; 1992 Feb; 111(2):244-8. PubMed ID: 1314812
[TBL] [Abstract][Full Text] [Related]
9. Conversion of fibrinogen to fibrin: mechanism of exposure of tPA- and plasminogen-binding sites.
Yakovlev S; Makogonenko E; Kurochkina N; Nieuwenhuizen W; Ingham K; Medved L
Biochemistry; 2000 Dec; 39(51):15730-41. PubMed ID: 11123898
[TBL] [Abstract][Full Text] [Related]
10. Identification and characterization of novel tPA- and plasminogen-binding sites within fibrin(ogen) alpha C-domains.
Tsurupa G; Medved L
Biochemistry; 2001 Jan; 40(3):801-8. PubMed ID: 11170397
[TBL] [Abstract][Full Text] [Related]
11. Monoclonal antibody interferes with fibrin binding of t-PA.
Matsuo O; Okada K; Fukao H; Tanaka N; Ueshima S
Thromb Res; 1988 Sep; 51(5):485-94. PubMed ID: 2459803
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of fibrinogen and fibrin products and isolated peptide chains on the fibrin-mediated stimulation of plasminogen activation by tissue-type plasminogen activator, and on the fibrin-dependent enhancement of the amidolytic activity of one-chain tissue-type plasminogen activator.
Fischer B
Biol Chem Hoppe Seyler; 1990 Nov; 371(11):1067-75. PubMed ID: 2128181
[TBL] [Abstract][Full Text] [Related]
13. Variants of human tissue-type plasminogen activator. Fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains.
Larsen GR; Henson K; Blue Y
J Biol Chem; 1988 Jan; 263(2):1023-9. PubMed ID: 3121618
[TBL] [Abstract][Full Text] [Related]
14. Antibody-directed fibrinolysis: a bispecific (Fab')2 that binds to fibrin and tissue plasminogen activator.
Runge MS; Bode C; Savard CE; Matsueda GR; Haber E
Bioconjug Chem; 1990; 1(4):274-7. PubMed ID: 2129015
[TBL] [Abstract][Full Text] [Related]
15. Study of tissue-type plasminogen activator binding sites on fibrin using distinct fragments of fibrinogen.
Grailhe P; Nieuwenhuizen W; Anglés-Cano E
Eur J Biochem; 1994 Feb; 219(3):961-7. PubMed ID: 8112348
[TBL] [Abstract][Full Text] [Related]
16. Fibronectin decreases the stimulatory effect of fibrin and fibrinogen fragment FCB-2 on plasmin formation by tissue plasminogen activator.
Beckmann R; Geiger M; de Vries C; Pannekoek H; Binder BR
J Biol Chem; 1991 Feb; 266(4):2227-32. PubMed ID: 1824940
[TBL] [Abstract][Full Text] [Related]
17. Characterization of monoclonal antibodies against human tissue plasminogen activator (tPA): quantitation of free tPA in human cell cultures by an ELISA.
Kurokawa T; Toyoda Y; Iwasa S
J Biochem; 1991 Feb; 109(2):217-22. PubMed ID: 1713912
[TBL] [Abstract][Full Text] [Related]
18. The activation of type 1 and type 2 plasminogen by type I and type II tissue plasminogen activator.
Mori K; Dwek RA; Downing AK; Opdenakker G; Rudd PM
J Biol Chem; 1995 Feb; 270(7):3261-7. PubMed ID: 7852411
[TBL] [Abstract][Full Text] [Related]
19. The tissue plasminogen activator finger domain confers fibrin-dependent enhancement of catalytic activity to single-chain urokinase-type plasminogen activator.
Lubin IM; Caban R; Runge MS
J Biol Chem; 1993 Mar; 268(8):5550-6. PubMed ID: 8449917
[TBL] [Abstract][Full Text] [Related]
20. The construction and expression of chimeric urokinase-type plasminogen activator genes containing kringle domains of human plasminogen.
Boutaud A; Castellino FJ
Arch Biochem Biophys; 1993 Jun; 303(2):222-30. PubMed ID: 8512311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
